keepMED

Company Overview

Snapshot

Founded in April 2012 by Alex Rapoport, keepMED operates with 1–10 employees. The company raised $25.63 million across 3 funding rounds from 9 investors.

Business overview

keepMED is a medical technology company focused on developing treatment solutions for obstructive sleep apnea. The company's core product is the keePAP device, a hose-less, wearable, therapeutic positive airway pressure (PAP) on-demand device designed to restore normal breathing with minimal airflow. This device is currently in clinical trials and aims to maintain airway patency by delivering intermittent, precise PAP. keepMED operates within the Health Tech & Life Sciences sector, specifically targeting digital healthcare and digital therapeutics for patients globally, including in Israel and the United States.

Strategic signal

In March 2023, keepMED ceased operations, indicating a significant shift in its business trajectory. This event signals to investors and innovation teams that the company is no longer actively pursuing its mission in the obstructive sleep apnea treatment market, prompting a re-evaluation of its impact and potential within the health tech landscape.

Company Intelligence Q&A

What is keepMED's primary focus?

keepMED is a medical technology company dedicated to providing treatment solutions to improve the health and quality of life for individuals suffering from obstructive sleep apnea.

What is the keePAP device?

The keePAP is a hose-less, wearable, therapeutic positive airway pressure (PAP) on-demand device developed by keepMED. It is designed to restore normal breathing gently and effectively with minimal airflow by maintaining airway patency.

When did keepMED cease operations?

keepMED ceased to operate in March 2023.